



Appendix 4D

For the Half Year Ended 31 December 2014

1. Results for announcement to the market

Current Reporting Period – Half Year Ended 31 December 2014

Previous Reporting Period – Half Year Ended 31 December 2013

This report is to be read in conjunction with the 30 June 2014 Annual Report and is given in compliance with Listing Rule 4.2A.

				\$'000
Revenues	up	39.42%	to	529
Loss after tax attributable to members	down	9.04%	to	(1,303)
Net loss for the period attributable to members	down	9.04%	to	(1,303)

2. Net Tangible Assets per Security (cents per share)

As at 31 December 2014 7.335*

As at 31 December 2013 (5.172)*

*Capital was consolidated on a 40:1 basis on 20th November 2014, comparative results for Net Tangible Assets and Loss per Share have been restated in this report to reflect this consolidation

3. Details of entities over which control has been gained or lost during the period

None

4. Details of individual and total dividends

None

5. Details of dividend reinvestment plans in operation

None

6. Details of Associates and Joint Ventures

None

7. These accounts have been subject to Review. Refer to the Auditor's Review Report on page 16.

Approved Date: Wednesday, 18th February 2015



Appendix 4D
Interim Financial Report

For the Half Year Ended 31 December 2014



To be read in conjunction with the 30 June 2014 Annual Report.
In compliance with Listing Rule 4.2A

Contents

Directors' Report	4
Auditor's Independence Declaration	6
Statement of Profit or Loss and Other Comprehensive Income	7
Statement of Financial Position	8
Statement of Changes in Equity	9
Statement of Cash Flows	10
Notes to the Financial Statements	11
Directors' Declaration	15
Independent Auditors' Review Report	16
Company Directory	18

This Half Year Financial Report does not include all notes of the type normal included in an Annual Financial Report. Accordingly, this report is to be read in conjunction with the Annual Financial Report for the year ended 30 June 2014 and any public announcements made by Immuron Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 and the ASX Listing Rules.

Directors' Report

Your Directors present their report on Immuron Limited for the half year ended 31 December 2014.

Directors

The following persons were directors of Immuron Limited during the whole of the half-year and up to the date of this report, unless otherwise stated:

Dr. Roger Aston	Non-Executive Chairman
Mr. Stephen Anastasiou	Non-Executive Director
Mr. Daniel Pollock	Non-Executive Director

Overview of Company's Activities

During the reporting period, Immuron Limited ("the Company" or "Immunon") continued development and commercialization of its hyperimmune colostrum platform products for the treatment and/or prevention of a number of diseases. The following report on operations details the company's commercialization efforts that focused on Travelan® and research and development activities that comprised principally the clinical development of Immuron's therapeutic candidate IMM-124E for the treatment of Non-Alcoholic SteatoHepatitis (NASH).

Review of Operations

Commercialization of Travelan continues to gain momentum

Immunon continued its focus on the global commercialization of Travelan. During the reporting period the company generated revenues from the sale of Travelan® of \$529,255, compared with \$379,615 in the corresponding period. This followed the Canadian launch of Travelan® in August 2014 by Paladin Labs. We expect our Travelan business to continue to grow as Paladin Labs generates momentum in Canada and other countries approve and launch our product. We expect further Travelan® revenues will come from our existing agreements with overseas licensees as well as from prospective international licensees with whom we are engaged in discussions. Of particular note are our distribution efforts in the US and China.

IMM-124E for Non-Alcoholic SteatoHepatitis (NASH):

During the reporting period the company's principal development focus was progressing towards commencement of the NASH clinical trials and the company accomplished significant progress in this program. Following completion of the trial protocol and investigators' brochure, the Company completed production of the clinical trial material for our NASH clinical trials and engaged the services of data management and clinical monitors. The appointed monitors assessed and approved the Company's selected hospital sites in Australia and the United States. Hospital ethics submissions were made with the first ethics approval attained in Australia. Additionally, specialist diagnostic service providers were engaged to support various assessments required in the study such as MRI, pathology and immunological tests.

IMM-124E for Alcoholic Steatohepatitis (ASH)

During the reporting period, we completed production of the clinical trial material for the ASH clinical trials sponsored and funded by the US National Institutes of Health. ASH has the same manifestation as NASH, and results from excessive consumption of alcohol.

IMM-529 for Clostridium difficile infection:

Clostridium difficile (C.difficile) is a bacteria normally found in human intestines. Under certain circumstances C.difficile can multiply and cause diarrhoea as well as potentially life-threatening intestinal conditions including colonic perforation and toxic megacolon. Deaths related to C.difficile increased 400% between 2000 and 2007, due in part to a stronger germ strain and antibiotic resistance.

IMM 529 is being designed to both prevent and treat C.difficile infections and whilst not a priority development focus for Immuron, it continues to progress.

Key announcements by date:

- 7 July 2014 - Immuron FY2014 Travelan® Sales Exceed \$1m
- 6 August 2014 - Paladin Labs Announces the Launch of Travelan® in Canada
- 2 September 2014 - Immuron Improves Hadasit Royalty Terms
- 15 October 2014 - Immuron provided an update in relation to the progress of its NASH and ASH trials
- 20 November 2014 - Immuron Completes Capital Consolidation
- 27 November 2014 - Ethics Approval Secured in all Australian NASH Trial Sites
- 18 December 2014 - Resignation of CEO

Immunon Limited's Business Strategy

Immunon's current strategy is to develop its product candidates to the stage where they can be sold or out-licensed to deliver greatest shareholder value. A key feature of the strategy is that any such license carries license fees but allows Immunon to maintain and control the supply and production of its hyperimmune colostrum derived products. The timing and the nature of the licenses will vary according to the profile and stage of development for each product as well as approvals from regulatory bodies.

Corporate

On 2 September 2014, the company announced that it entered into an amended agreement for reduced royalty payment obligations to Hadasit Medical Research Services & Development Limited. The royalties had been amended so that they are now derived from net income received by Immunon rather than from revenues received by a licensee of Immunon, thereby providing further certainty in the commercialization of Immunon's NASH product and any other prescription product developed with the intellectual property assigned by Hadasit to Immunon. Immunon also reduced the royalty payable on all its over-the-counter products

On 20 November 2014, the company announced that it had completed a consolidation of the securities of the Company on a 1:40 basis, following shareholder approval at the company's Annual General Meeting convened on 13 November 2014.

On 18 December 2014, the company announced the resignation of Amos Meltzer as its Chief Executive Officer.

Significant Events after Reporting Date

There have not been any matters or circumstances in the financial statements or notes thereto, that have arisen since the end of the financial half year, which significantly affected, or may significantly affect, the operations of Immunon Limited, the results of those operations or the state of affairs of Immunon Limited in future financial years.

Auditors Independence Declaration

A copy of the Auditors Independence Declaration as required under section 307C of the Corporations Act 2001 is set out on page 6.



Dr. Roger Aston
Non-Executive Chairman
Immunon Limited

This the 18th Day of February 2015

**AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE
CORPORATIONS ACT 2001 TO THE DIRECTORS OF IMMURON LIMITED**

I declare that, to the best of my knowledge and belief during the year ended 31 December 2014 there have been:

- no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and
- no contraventions of any applicable code of professional conduct in relation to the audit.

A handwritten signature in blue ink that reads 'William Buck'.

William Buck Audit (VIC) Pty Ltd
ABN 59 116 151 136

A handwritten signature in blue ink that appears to read 'J.C. Luckins'.

J.C. Luckins
Director

Dated this 18th day of February, 2015

**CHARTERED ACCOUNTANTS
& ADVISORS**

Melbourne Office
Level 20, 181 William Street
Melbourne VIC 3000

Hawthorn Office
Level 1, 465 Auburn Road
Hawthorn East VIC 3123

PO Box 185, Toorak VIC 3142
Telephone: +61 3 9824 8555
williambuck.com

Statement of Profit or Loss and Other Comprehensive Income

For the Half Year Ended 31 December 2014

	Note	31 Dec 2014 \$	31 Dec 2013 \$
Revenue			
Total Operating Revenue		529,255	379,615
Total Revenue		529,255	379,615
Cost of Goods Sold		(161,802)	(100,326)
Gross Profit		367,453	279,289
Direct Selling Costs			
Sales and Marketing Costs		(204,346)	(144,461)
Freight Costs		(4,713)	(3,812)
		158,394	131,016
Other Income		782,651	199,118
Expenses			
Amortisation Expenses		-	(368,148)
Consulting, Employee and Director Expenses		(276,192)	(442,277)
Corporate Administration Expenses		(276,525)	(383,091)
Depreciation Expenses		(1,893)	(1,910)
Finance Costs		-	(195,580)
Impairment of Inventory		(15,192)	-
Marketing and Promotion Expenses		(115,389)	(25,928)
Research and Development Expenses		(1,523,921)	(326,521)
Travel and Entertainment Expenses		(34,464)	(18,715)
Loss Before Income Tax		(1,302,531)	(1,432,036)
Income Tax Expense		-	-
Loss for the Period Attributable to Members of Immuron Limited		(1,302,531)	(1,432,036)
Other Comprehensive Income for the Period		-	-
Total Comprehensive Loss for the Period		(1,302,531)	(1,432,036)
Loss per share for the period attributable to members of Immuron Limited			
Basic and Diluted Loss per Share (Cents per Share)	7	(1.739)	(5.515)

The above Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes

Statement of Financial Position

For the Half Year Ended 31 December 2014

	Note	31 Dec 2014 \$	30 June 2014 \$
ASSETS			
Current Assets			
Cash and cash equivalents		4,570,813	6,141,789
Trade and other receivables		972,565	517,792
Inventories		518,682	565,957
Other		411,592	386,641
Total Current Assets		6,473,652	7,612,179
Non-Current Assets			
Investments		1	1
Property, plant and equipment		18,173	20,065
Total Non-Current Assets		18,174	20,066
TOTAL ASSETS		6,491,826	7,632,245
LIABILITIES			
Current Liabilities			
Trade and other payables		992,986	845,300
Total Current Liabilities		992,986	845,300
TOTAL LIABILITIES		992,986	845,300
NET ASSETS		5,498,840	6,786,945
EQUITY			
Issued capital	5	40,335,347	40,325,295
Reserves	6	670,967	666,592
Accumulated Losses		(35,507,474)	(34,204,942)
TOTAL EQUITY		5,498,840	6,786,945

The above Statement of Financial Position should be read in conjunction with the accompanying notes

Statement of Changes in Equity

For the Half Year Ended 31 December 2014

	Share Capital	Option Reserve	Accumulated Losses	Total
	\$	\$	\$	\$
Balance as at 30 June 2013	31,357,697	1,208,271	(32,420,982)	144,986
Total comprehensive loss for the period:	-	-	(1,432,036)	(1,432,036)
<i>Transactions with Equity holders in their capacity as equity holders:</i>				
Shares issued net of issue costs	34,257	-	-	34,257
Options issued	-	197,159	-	197,159
Employee and consultants share options				
- Value of services	-	5,749	-	5,749
Balance at 31 December 2013	31,391,954	1,411,179	(33,853,018)	(1,049,885)
Total comprehensive loss for the period:	-	-	(1,112,515)	(1,112,515)
<i>Transactions with Equity holders in their capacity as equity holders:</i>				
Shares issued net of issue costs	8,933,340	-	-	8,933,340
Options issued	-	14,563	-	14,563
Employee and consultants share options				
- Value of services	-	1,441	-	1,441
Lapse or exercise of share options	-	(760,591)	760,591	-
Balance at 30 June 2014	40,325,295	666,592	(34,204,942)	6,786,945
Total comprehensive loss for the period:	-	-	(1,302,531)	(1,302,531)
<i>Transactions with Equity holders in their capacity as equity holders:</i>				
Shares issued net of issue costs	10,052	-	-	10,052
Employee and consultants share options				
- Value of services	-	4,375	-	4,375
Balance at 31 December 2014	40,335,347	670,967	(35,507,474)	5,498,840

The above Statement of Changes in Equity should be read in conjunction with the accompanying notes

Statement of Cash Flows

For the Half Year Ended 31 December 2014

	31 Dec 2014 \$	31 Dec 2013 \$
<u>Cash flows from operating activities</u>		
Receipts from customers	820,613	287,824
Payments to suppliers and employees	(2,428,109)	(1,438,749)
Interest received	63,814	11,710
Interest and other costs of finance paid	-	(88,916)
Receipt of R&D tax refund	-	187,407
Net cash inflows/(outflows)	(1,543,683)	(1,040,724)
<u>Cash flows related to investing activities</u>		
Payment for purchases of plant and equipment	-	-
Net investing cash inflows/(outflows)	-	-
<u>Cash flows related to financing activities</u>		
Proceeds from issues of equity securities	-	-
Capital raising costs	-	(51,785)
Net financing cash inflows/(outflows)	-	(51,785)
Net increase/(decrease) in cash and cash equivalents	(1,543,683)	(1,092,509)
Cash and cash equivalents at the beginning of the period	6,141,789	1,446,712
Cash and cash equivalents at the end of the period	4,598,106	354,203

The above Statement of Cash Flows should be read in conjunction with the accompanying notes

Notes to the Financial Statements

Note 1. Basis of Preparation

(a) Basis of Preparation

The general purpose financial report for the interim half year reporting period ended 31 December 2014 has been prepared in accordance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001.

This half year financial report does not include all notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2014 and any public announcements made by Immuron Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 and the ASX Listing Rules.

Compliance with AASB 134 "Interim Financial Report" ensures that the financial statements and notes of the entity comply with International Financial Reporting Standards equivalent IAS 34 "Interim Financial Reporting."

(b) Accounting Policies

All accounting policies adopted are consistent with the most recent Annual Financial Report for the year ended 30 June 2014.

Note 2. Dividends

The company has not declared any dividends in the period ended 31 December 2014. (2013: \$Nil)

Note 3. Segment Information

The entity has identified its operating segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the allocation of resources.

The executive management team considers the business from both a product and a geographic perspective and has identified three reportable segments.

Segments

Research and Development (R&D) – Income and expenses directly attributable to the company's research and development projects performed in Australia and Israel.

HyperImmune Products – Income and expenses directly attributable to Travelan activities which occur in Australia, New Zealand and Canada.

Corporate – Other items of income and expenses not directly attributable to R&D or HyperImmune Products segment are disclosed as corporate costs. Corporate activities primarily occur within Australia. This segment includes interest expenses from financing activities and depreciation.

The Board assesses the performance of the operating segments at a number of operating levels including adjusted EBITDA.

Notes to the Financial Statements (Continued...)

31 December 2014	R&D	HyperImmune Products	Corporate	Total
	\$	\$	\$	\$
Segment Revenue				
Revenue from external customers	-	529,255	-	529,255
R&D tax offset refund	713,632	-	-	713,632
Interest revenue	-	-	69,019	69,019
Total Segment Revenue	713,632	529,255	69,019	1,311,906
Segment Expenses				
Segment Expenses	(1,523,921)	(386,053)	(704,463)	(2,614,437)
Total Segment Expense	(1,523,921)	(386,053)	(704,463)	(2,614,437)
Income Tax Expense	-	-	-	-
Net Result	(810,289)	143,202	(635,444)	(1,302,531)
Assets				
Segment assets	-	1,092,124	5,399,702	6,491,826
Total Assets	-	1,092,124	5,399,702	6,491,826
Liabilities				
Segment liabilities	(603,306)	(236,666)	(153,014)	(992,986)
Total Liabilities	(603,306)	(236,666)	(153,014)	(992,986)

31 December 2013	R&D	HyperImmune Products	Corporate	Total
	\$	\$	\$	\$
Segment Revenue				
Revenue from external customers	-	379,615	-	379,615
Interest revenue	187,407	-	-	187,407
Other gains/(losses)	-	-	11,711	11,711
Total Segment Revenue	187,407	379,615	11,711	578,733
Segment Expenses				
Segment Expenses	(694,669)	(248,599)	(1,067,501)	(2,010,769)
Total Segment Expense	(694,669)	(248,599)	(1,067,501)	(2,010,769)
Income Tax Expense	-	-	-	-
Net Loss	(507,262)	131,016	(1,055,790)	(1,432,036)

30 June 2014	R&D	HyperImmune Products	Corporate	Total
	\$	\$	\$	\$
Assets				
Segment assets	-	1,409,670	6,222,575	7,632,245
Total Assets	-	1,409,670	6,222,575	7,632,245
Liabilities				
Segment liabilities	(360,214)	(252,334)	(232,752)	(845,300)
Total Liabilities	(360,214)	(252,334)	(232,752)	(845,300)

Notes to the Financial Statements (Continued...)

Note 4. Contingent Liabilities and Assets

There has been no change in contingent liabilities and assets since the last annual reporting date.

Note 5. Contributed Equity

	31 December 2014		30 June 2014	
	No.	\$	No.	\$
Fully Paid Ordinary Shares				
Balance at beginning of period	2,995,662,120	40,325,295	1,035,450,143	31,357,697
Share issued during the period	72,916	11,667	1,960,211,977	9,792,599
Shares to be issued	-	-	-	(5,833)
Transaction costs relating to share issues (Cash-based)	-	(1,614)	-	(819,168)
Transaction costs relating to share issues (Non-cash)	-	-	-	-
Consolidation of shares on a 40:1 basis	(2,920,770,804)		-	
Total Issued Capital	74,964,232	40,335,347	2,995,662,120	40,325,295

Note 6. Option Reserves

	31 December 2014		30 June 2014	
	No.	\$	No.	\$
Options over fully paid ordinary shares				
Balance at beginning of period	365,542,766	666,592	289,860,577	1,208,271
Options over ordinary shares issued during the period	-	-	87,963,494	211,721
Shares issued from the exercise of options	-	-	(29,075)	-
Option expense recorded over the vesting period	-	4,375	-	7,191
Lapse of options due to nil exercise	-	-	(12,252,230)	(760,591)
Consolidation of options on a 40:1 basis	(356,436,143)	-	-	-
Total Reserves	9,106,623	670,967	365,542,766	666,592

Note 7. Loss Per Share

	31 December 2014	31 December 2013
Basic and Diluted loss per share (cents)	(1.739)	(5.515)
a) Net loss used in the calculation of basic and diluted loss per share	(\$1,302,531)	(\$1,432,036)
b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share	74,907,491	25,965,944
c) Options that are considered to be potential ordinary shares are excluded from the weighted average number of ordinary shares used in the calculation of basic loss per share. All the options on issue do not have the effect of diluting the loss per share therefore, they have been excluded from the calculation of diluted loss per share.		

Note 8. Events Occurring after the Reporting Date

There have not been any matters or circumstances in the financial statements or notes thereto, that have arisen since the end of the financial half year, which significantly affected, or may significantly affect, the operations of Immuron Limited, the results of those operations or the state of affairs of Immuron Limited in future financial years.

Directors' Declaration

The directors of the company declare that:

1. The financial statements and notes, as set out on pages 7 to 14, are in accordance with the Corporations Act 2001 and other mandatory professional reporting requirements including:

- (a) complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations; and
- (b) giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the half-year ended on that date

2. In the Directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

A handwritten signature in blue ink, appearing to read 'RAA', with a horizontal line extending to the right.

Dr. Roger Aston
Non-Executive Chairman
Immuron Limited

This the 18th Day of February 2015

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF IMMURON LIMITED

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Immuron Limited (the company), which comprises the statement of financial position as at 31 December 2014, the statement of profit or loss and other comprehensive income, the statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the Corporations Act 2001 including:

- giving a true and fair view of the company's financial position as at 31 December 2014 and its performance for the half-year ended on that date; and
- complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

As the auditor of Immuron Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

CHARTERED ACCOUNTANTS & ADVISORS

Melbourne Office
Level 20, 181 William Street
Melbourne VIC 3000

Hawthorn Office
Level 1, 465 Auburn Road
Hawthorn East VIC 3123

PO Box 185, Toorak VIC 3142
Telephone: +61 3 9824 8555
williambuck.com

**INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF IMMURON LIMITED
(CONT)**

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Immuron Limited is not in accordance with the Corporations Act 2001 including:

- a) giving a true and fair view of the company's financial position as at 31 December 2014 and of its performance for the half year ended on that date; and
- b) complying with Australian Accounting Standard 134 Interim Financial Reporting and the Corporations Regulations 2001.

Matters Relating to the Electronic Presentation of the Reviewed Half Year Financial Report

This auditor's review report relates to the half year financial report of Immuron Limited for the half year ended 31 December 2014 included on Immuron Limited's web site. The company's directors are responsible for the integrity of the Immuron Limited's web site. We have not been engaged to report on the integrity of the Immuron Limited's web site. The auditor's review report refers only to the half year financial report. It does not provide an opinion on any other information which may have been hyperlinked to/from these statements. If users of this report are concerned with the inherent risks arising from electronic data communications they are advised to refer to the hard copy of the reviewed half year financial report to confirm the information included in the reviewed financial report presented on this web site.

William Buck.

William Buck Audit (VIC) Pty Ltd
ABN 59 116 151 136

A stylized blue ink signature, likely belonging to J.C. Luckins, consisting of a large 'J' and 'L' followed by a horizontal line.

J.C. Luckins
Director

Dated this 18th day of February, 2015

Company Directory

Australian Company Number (ACN)
063 114 045

Immuron Limited is a Public Company Limited by shares and is domiciled in Australia.

Directors

Dr. Roger Aston
Mr. Stephen Anastasiou
Mr. Daniel Pollock

Non-Executive Chairman
Non-Executive Director
Non-Executive Director

Chief Executive Officer (CEO)
Mr. Amos Meltzer

Company Secretaries
Mr. Phillip Hains
Mr. Peter Vaughan

Principal Place of Business

Level 1, 18 Kavanagh Street,
Southbank, Victoria, 3006
Australia
Telephone: + 61 (0)3 8648 4530
Facsimile: + 61 (0)3 9686 9460

Registered Office

Suite 1, 1233 High Street
Armadale, Victoria, 3143
Australia
Telephone: + 61 (0)3 9824 5254
Facsimile: + 61 (0)3 9822 7735

Share Registry

Security Transfer Registrars
770 Canning Highway
Applecross WA 6153
Telephone: +61 (0)8 9315 2333
Facsimile: +61 (0)8 9315 2233

Solicitors

K&L Gates LLP
Level 25, 525 Collins Street
Melbourne Victoria, 3000
Australia
Telephone: + 61 (0)3 9205 2000
Facsimile: + 61 (0)3 9205 2055

Auditors

William Buck
Level 20, 191 William Street
Melbourne, Victoria, 3000
Australia
Telephone: + 61 (0)3 9824 8555
Facsimile: + 61 (0)3 9824 8580

Bankers

National Australia Bank (NAB)
330 Collins Street,
Melbourne, Victoria, 3000
Australia

Websites

www.immuron.com www.travelan.com.au

Securities Quoted

Australian Securities Exchange

- Ordinary Fully Paid Shares (Code: IMC)
- Listed Options over Ordinary Fully Paid Shares (Code: IMCOA)
exercisable at \$1.556 per option on or before 30 April 2015.